BioTuesdays

Category - Markets

Flex Pharma
Markets

Roth restarts Flex Pharma at buy

Roth Capital Partners reinitiated coverage of Flex Pharma (NASAQ:FLKS) with a “buy” rating and $14 price target. The stock closed at $3.37 on Sept. 6. Flex is developing FLX-787, an innovative anti-cramp drug in...

September 7, 2017
Verastem
Markets

HCW ups Verastem price target to $10

H.C. Wainwright raised its price target for Verastem (NASDAQ:VSTM) to $10 from $6.50 after the company reported positive top-line results from a Phase DUO study of duvelisib for the treatment of relapsed/refractory...

September 7, 2017
theralase logo
Markets

Echelon starts Theralase at speculative buy

Echelon Wealth Partners initiated coverage of Theralase Technologies (TSXV:TLT) with a “speculative buy” rating and one-year price target of 90 cents. The stock closed at 47 cents on Sept. 1. Analyst Doug Loe writes...

September 5, 2017
Clementia
Markets

BTIG starts Clementia at buy

BTIG initiated coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with a “buy” rating and 12-month price target of $32, saying the company’s lead molecule, palovarotene, presents a plethora of promising possibilities...

August 31, 2017
Gemphire Logo
Markets

HCW starts Gemphire at buy

H.C. Wainwright launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and a price target of $21, saying it views the sell off in the shares following results of the ROYAL-1 clinical trial as...

August 31, 2017
KalVista Pharmaceuticals Logo
Markets

BTIG starts KalVista at buy

BTIG launched coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a “buy” rating and $18 price target. The stock closed at $6.59 on August 30. KalVista is focused on developing a portfolio of oral plasma kallikrein...

August 31, 2017
Innate Pharma Logo
Markets

HCW starts Innate Pharma at buy

H.C. Wainwright initiated coverage of French-based Innate Pharma (PSE:IPH) with a “buy” rating and price target of €16.50. The stock closed at €10.70 on August 29. Analyst Swayampakula Ramakanth writes that Innate is...

August 30, 2017
Intra Cellular Therapies
Markets

Ladenburg ups Intra-Cellular to buy

Ladenburg Thalmann upgraded Intra-Cellular Therapies (NASDAQ:ITCI) to “buy” from “neutral” with a $36 price target, reflecting a positive update from the FDA about the company’s schizophrenia program. The stock closed...

August 30, 2017
Clementia
Markets

Leerink starts Clementia at OP

Leerink launched coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with an “outperform” rating and $23 price target. The stock closed at $16.11 on August 25. Clementia’s lead asset, palovarotene, is a small molecule...

August 28, 2017
Foamix Pharmaceuticals
Markets

HCW starts Foamix at buy

H.C. Wainwright initiated coverage of Foamix Pharmaceuticals (NASDAQ:FOMX) with a “buy” rating and $12 price target. The stock closed at $4.53 on Aug. 23. Analyst Raghuram Selvaraju writes that Foamix is a rapidly...

August 24, 2017